RSS   Newsletter   Contact   Advertise with us
Post Online Media

United Therapeutics buys Arena's hypertension drug ralinepag in deal worth $1.2 billion

Share on Twitter Share on LinkedIn
Staff Writer |
United Therapeutics
Acquisition   Arena will grant United Therapeutics exclusive rights

Arena Pharmaceuticals and United Therapeutics Corporation announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).


Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.

In return, Arena will receive up to $1.2 billion, including an upfront payment of $800 million and potential milestone payments totaling up to $400 million based on the achievement of certain regulatory events. Additionally, Arena will receive low double-digit tiered royalties on annual net sales of ralinepag.


What to read next
POST Online Media Contact